Related references
Note: Only part of the references are listed.The impact of the globalization of cancer clinical trials on the enrollment of Black patients
Serena Tharakan et al.
CANCER (2021)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Jonathan L. Kaufman et al.
BLOOD (2020)
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study
Nathanael R. Fillmore et al.
BLOOD (2019)
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Paul G. Richardson et al.
BLOOD CANCER JOURNAL (2018)
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
Luciano J. Costa et al.
BLOOD ADVANCES (2017)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups
Sikander Ailawadhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Management of treatment-emergent peripheral neuropathy in multiple myeloma
P. G. Richardson et al.
LEUKEMIA (2012)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Share Paper
